Financial Results and Upcoming Conference Calls - Research Report on Ariad, Idenix, Osiris, InterMune, and Array BioPharma

 Financial Results and Upcoming Conference Calls - Research Report on Ariad,
                Idenix, Osiris, InterMune, and Array BioPharma

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Ariad
Pharmaceuticals Inc. (NASDAQ: ARIA), Idenix Pharmaceuticals Inc. (NASDAQ:
IDIX), Osiris Therapeutics, Inc. (NASDAQ: OSIR), InterMune Inc. (NASDAQ:
ITMN), and Array BioPharma, Inc. (NASDAQ: ARRY). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Ariad Pharmaceuticals Inc. Research Report

On October 31, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced the change
in date of its Q3 2013 conference call from Wednesday, November 6, 2013 to
Tuesday, November 12, 2013, at 8:30 a.m. EST. The Company informed that the
live webcast of the call will be available under "Investor" section of its
website and the replay of the same will be available for three weeks on the
same location beginning approximately two hours after completion of the call.
The Full Research Report on Ariad Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/161c_ARIA]

--

Idenix Pharmaceuticals Inc. Research Report

On October 30, 2013, Idenix Pharmaceuticals Inc. (Idenix) reported its Q3 2013
results. Idenix registered total revenues of $19,000 in Q3 2013, compared to
$32.3 million in Q3 2012. The Company posted a net loss of c.$34 million or
$0.25 per diluted share compared to a net income of $4.3 million or $0.03 per
diluted share in Q3 2012. Ron Renaud, Idenix's President and CEO, said, "A key
objective for our development teams has been to commence a clinical trial for
our nucleotide prodrug program this year. Based on the differentiated profile
we've seen in our preclinical research, we believe IDX21437 has strong
potential to be a key component of a fixed-dose all-oral pan-genotypic
regimen, specifically in combination therapy with our NS5A inhibitor." Idenix
stated that cash and cash equivalents totaled $148.8 million for Q3 2013,
compared with $251.9 million in Q3 2012, which the Company expects to be
sufficient to sustain its operations through December 2014. The Full Research
Report on Idenix Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.AnalystsCorner.com/r/full_research_report/c979_IDIX]

--

Osiris Therapeutics, Inc. Research Report

On November 1, 2013, Osiris Therapeutics, Inc. (Osiris) announced its Q3 2013
results with product revenues reported at $6.9 million, up 219.9% YoY. The
Company posted a net loss of $1.7 million or $0.05 per diluted share for Q3
2013, compared to $2.9 million or $0.09 per diluted share in Q3 2012. C.
Randal Mills, Ph.D., President and CEO of Osiris, said, "We have now
successfully transformed Osiris from a concept into a biotechnology reality
with positive cash flow, expanding product sales, a strong balance sheet, no
debt and a solid pipeline. Importantly, we have accomplished this with minimal
dilution to our shareholders. While these results clearly set Osiris apart in
the stem cell industry, the team is focused solely on realizing the
opportunities ahead of us." The Full Research Report on Osiris Therapeutics,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/82ba_OSIR]

--

InterMune Inc. Research Report

On October 30, 2013, InterMune Inc. (InterMune) reported its Q3 2013 financial
results. Esbriet net revenues arrived at $19.7 million representing an
increase of 161.7% YoY. The Company informed that Esbriet is its product
marketed in Europe and Canada for the treatment of adult patients with mild to
moderate idiopathic pulmonary fibrosis. The Company posted a net loss of $49.9
million or $0.61 per basic share compared to a net loss of $40.9 million or
$0.63 per basic share in Q3 2012. Dan Welch, Chairman, CEO, and President of
InterMune stated, "Notably, Esbriet revenue growth in the third quarter came
from both new country launches and growth in countries where the product has
been available. During the quarter we launched Esbriet in Italy and the UK,
two of the five largest countries in Europe, as well as in Finland and
Ireland. Esbriet revenue grew in the third quarter in countries where Esbriet
had previously been launched, with Germany, France, the mid-sized European
countries and Canada all reporting sequential double-digit growth." For
full-year 2013, the Company revised its guidance of net revenue from Esbriet
to range within $60 million to $70 million. The Full Research Report on
InterMune Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/dd8c_ITMN]

--

Array BioPharma, Inc. Research Report

On October 31, 2013, Array BioPharma, Inc. (Array BioPharma) reported its Q1
FY 2014 results (period ended September 30, 2013). Total revenues were
reported at $14.2 million, compared to $15.8 million in Q1 FY 2013. The
Company posted a net loss of $15.7 million or $0.13 per diluted share,
compared to a net loss of $11.8 million or $0.13 per diluted share in Q1 FY
2013. Ron Squarer, CEO of Array, stated, "Array is taking an important step
today by announcing plans to initiate a Phase 3 trial in 2014 with our
wholly-owned multiple myeloma asset, ARRY-520. In addition, we are excited
that five registration trials are already enrolling patients with our
partnered MEK inhibitors, selumetinib and MEK162, with another pivotal trial
expected to start by year-end." The Full Research Report on Array BioPharma,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/e048_ARRY]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)